Monoclonal antibodies that react with the capsule of Bacillus anthracis

Patent metadata

Field	Value
Publication number	US-9273124-B2
Application number	US-201313935956-A
Country	US
Kind code	B2
Filing date	Jul 5, 2013
Priority date	Nov 19, 2008
Publication date	Mar 1, 2016
Grant date	Mar 1, 2016

Abstract

The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of Bacillus anthracis . The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.

First claim

We claim:

1. A method for protecting a subject from a Bacillus anthracis infection, comprising:
selecting a subject with a Bacillus anthracis infection or suspected of having a Bacillus anthracis infection; and
administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an isolated monoclonal antibody or antigen binding fragment thereof and a pharmaceutically acceptable carrier,
wherein the monoclonal antibody or antigen binding fragment comprises a heavy chain (H) with a H-complementarity determining region (CDR)1, H-CDR2 and H-CDR3 region and a light chain (L) with a L-CDR1, L-CDR2 and L-CDR3 region, wherein:
(a) the heavy chain of the monoclonal antibody or antigen binding fragment comprises the H-CDR1, H-CDR2 and H-CDR3 of SEQ ID NO: 3 and the light chain of the monoclonal antibody or antigen binding fragment comprises the L-CDR1, L-CDR2 and L-CDR3 of SEQ ID NO: 4; or
(b) the heavy chain of the monoclonal antibody or antigen binding fragment comprises the H-CDR1, H-CDR2 and H-CDR3 of SEQ ID NO: 5 and the light chain of the monoclonal antibody or antigen binding fragment comprises the L-CDR1, L-CDR2 and L-CDR3 of SEQ ID NO: 6,
and wherein the antibody or antigen binding fragment specifically binds poly-γ-D-glutamic acid (γDPGA),
thereby protecting the subject from the Bacillus anthracis infection.

2. The method of claim 1 , wherein
(a) the H-CDR1 comprises the amino acid sequence set forth as amino acids 28 to 32 of SEQ ID NO: 3, the H-CDR2 comprises the amino acid sequence set forth as amino acids 47 to 55 of SEQ ID NO: 3, and the H-CDR3 comprises the amino acid sequence set forth as amino acids 95 to 111 of SEQ ID NO: 3, and wherein the antibody has a light chain with a L-CDR 1, L- CDR2 and L-CDR3 region, and wherein L-CDR1 comprises the amino acid sequence set forth as amino acids 23 to 33 of SEQ ID NO: 4, L-CDR2 comprises the amino acid sequence set forth as amino acids 48 to 55 of SEQ ID NO: 4, and L-CDR3 comprises the amino acid sequence set forth as amino acids 88 to 96 of SEQ ID NO: 4; or
(b) wherein H-CDR1 comprises the amino acid sequence set forth as amino acids 27 to 31 of SEQ ID NO: 5, H-CDR2 comprises the amino acid sequence set forth as amino acids 46 to 54 of SEQ ID NO: 5, and H-CDR3 comprises the amino acid sequence set forth as amino acids 94 to 110 of SEQ ID NO: 5 and wherein the antibody has light chain with a L-CDR1, L-CDR2 and L-CDR3 region, and wherein L-CDR1 comprises the amino acid sequence set forth as amino acids 22 to 32 of SEQ ID NO: 6, L-CDR2 comprises the amino acid sequence set forth as amino acids 47 to 54 of SEQ ID NO: 6, and L-CDR3 comprises the amino acid sequence set forth as amino acids 87 to 95 of SEQ ID NO: 6.

3. The method of claim 2 , wherein:
(a) the heavy chain comprises the amino acid sequence according to SEQ ID NO. 3; and the light chain comprises the amino acid sequence according to SEQ ID NO. 4; or
(b) the heavy chain comprises the amino acid sequence according to SEQ ID NO. 5; and the light chain comprises the amino acid sequence according to SEQ ID NO. 6.

4. The method of claim 2 , further comprising, administering to the subject a therapeutically effective amount of one or more isolated anti-anthrax toxin antibodies or a fragment thereof.

5. The method of claim 4 , wherein the one or more isolated anti-anthrax toxin antibodies or a fragment thereof comprises one or more of an anti-protective antigen (PA), -lethal factor (LF), or -edema factor (EF) antibody or a fragment thereof.

6. The method of claim 2 , wherein protecting the subject from the Bacillus anthracis infection comprises protecting the subject from a subsequent challenge with Bacillus anthracis spores.

7. The method of claim 2 , wherein the antigen binding fragment is a Fab′ fragment, a F(ab)′ 2 fragment, a single chain Fv protein (scFv), or a disulfide stabilized Fv protein (dsFv).

8. The method of claim 6 , wherein the antibody is an IgG.

9. The method of claim 8 , wherein the antibody comprises a human γ1 constant region.

10. The method of claim 6 , wherein the antibody or antigen binding fragment is humanized.

11. The method of claim 6 , wherein the pharmaceutical composition is administered to the subject after exposure to Bacillus anthracis.

12. The method of claim 6 , wherein the subject is a human.

13. The method of claim 6 , wherein the pharmaceutical composition is administered intramuscularly.

14. The method of claim 7 , wherein (a) the H-CDR1 comprises the amino acid sequence set forth as amino acids 28 to 32 of SEQ ID NO: 3, the H-CDR2 comprises the amino acid sequence set forth as amino acids 47 to 55 of SEQ ID NO: 3, and the H-CDR3 comprises the amino acid sequence set forth as amino acids 95 to 111 of SEQ ID NO: 3, and wherein the antibody has a light chain with a L-CDR1, L-CDR2 and L-CDR3 region, and wherein L-CDR1 comprises the amino acid sequence set forth as amino acids 23 to 33 of SEQ ID NO: 4, L-CDR2 comprises the amino acid sequence set forth as amino acids 48 to 55 of SEQ ID NO: 4, and L-CDR3 comprises the amino acid sequence set forth as amino acids 88 to 96 of SEQ ID NO: 4.

15. The method of claim 7 wherein H-CDR1 comprises the amino acid sequence set forth as amino acids 27 to 31 of SEQ ID NO: 5, H-CDR2 comprises the amino acid sequence set forth as amino acids 46 to 54 of SEQ ID NO: 5, and H-CDR3 comprises the amino acid sequence set forth as amino acids 94 to 110 of SEQ ID NO: 5 and wherein the antibody has light chain with a L-CDR1, L-CDR2 and L-CDR3 region, and wherein L-CDR1 comprises the amino acid sequence set forth as amino acids 22 to 32 of SEQ ID NO: 6, L-CDR2 comprises the amino acid sequence set forth as amino acids 47 to 54 of SEQ ID NO: 6, and L-CDR3 comprises the amino acid sequence set forth as amino acids 87 to 95 of SEQ ID NO: 6.

Assignees

• Us Health
• Us Health

Inventors

• Chen Zhaochun
• Purcell Robert H
• Schneerson Rachel
• Kubler-Kielb Joanna
• Dai Lily Z

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• G01N2333/32

  from Bacillus (G) · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• G01N33/56911

  Bacteria · CPC title